INmune Bio Announces Publication of Data on INKmune Primed NK cells in Peer-Reviewed Journal PLOS ONE

LA JOLLA, Calif., June 27, 2019 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB), an immunotherapy company developing treatments that harness the patient’s innate immune system to fight disease, announced today that the peer-reviewed open access scientific journal PLOS ONE published an article titled: “Tumor- and cytokine-primed human natural killer cells exhibit

Click to view original post